What it is
Efpeglenatide is a GLP-1 receptor agonist, a drug that switches on the receptor for GLP-1, given as an injection under the skin12. GLP-1 is a hormone the gut releases after a meal, and it helps control blood sugar and appetite1. South Korea's drug regulator says efpeglenatide acts on GLP-1 receptors in the brain and gut, curbing appetite and slowing how fast food leaves the stomach, so fullness lasts longer1. It's based on exendin-4, a peptide first found in the venom of the Gila monster, a lizard (Heloderma suspectum), rather than on human GLP-134512. That part is joined to a piece of a human antibody (an Fc fragment), which slows how fast the body clears it5. In early studies in people with type 2 diabetes, its half-life, the time it takes for half a dose to clear, ranged from 135 to 180 hours6.
What makes it distinct
Its phase 3 obesity trial was run in South Korea, in 448 adults without diabetes2. South Korea approved it in October 2026 for that same group: adults with obesity or overweight who don't have diabetes1.
What the evidence shows
Its earlier phase 3 trials were in people with type 2 diabetes7813. AMPLITUDE-O, funded by Sanofi, gave 4,076 people with type 2 diabetes weekly efpeglenatide or a placebo; they had heart and blood vessel disease, or kidney disease plus another heart risk factor3. Over a median of 1.81 years, meaning half were followed for longer and half for less, fewer people on efpeglenatide had a major heart event, such as a heart attack, a stroke or a death from heart or blood vessel disease, than people on placebo3. Fewer also had a drop in kidney function or a high level of protein in their urine3. In AMPLITUDE-M, adults with type 2 diabetes that diet and exercise alone weren't controlling saw their HbA1c, a blood test of average blood sugar, fall more on efpeglenatide than on placebo7. For weight, a phase 2 trial in 297 adults with obesity or overweight and no diabetes found more weight loss than placebo over 20 weeks911. Hanmi Pharmaceutical's phase 3 trial then compared weekly injections with a placebo in 448 adults in South Korea with obesity, or overweight and a related health problem, and no diabetes, with weight change at 40 weeks as its main measure2. In the diabetes trials, stomach and gut side effects were the most common, in line with other GLP-1 drugs78.
Open questions
- Full results of the Korean phase 3 obesity trial. No results are posted on its trial record2.
- Whether the heart and kidney results apply to people without diabetes. AMPLITUDE-O enrolled only people with type 2 diabetes and heart, blood vessel or kidney disease3.
- How the obesity results apply outside South Korea. The phase 3 obesity trial was run only there2. The earlier phase 2 weight trial was run in the US11.
- Longer-term effects on weight. The phase 2 trial ran for 20 weeks, and the phase 3 trial's record lists weight measures up to 64 weeks, with no results posted92.
Worth knowing
Sanofi ran four of its phase 3 diabetes trials, including AMPLITUDE-O, and ClinicalTrials.gov lists all four as stopped early by a sponsor decision not related to safety10131415. The paper reporting three of them says they ended because of funding, not because of concerns about safety or how well it worked8.
Sources
- Ministry of Food and Drug Safety (South Korea) press release, 7 October 2026: approval of 에페오토인젝터주 (efpeglenatide), a domestically developed obesity treatment
- ClinicalTrials.gov NCT06174779: Phase 3 study of HM11260C in adult obesity patients without diabetes mellitus (Hanmi)
- Gerstein HC et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (AMPLITUDE-O). N Engl J Med 2021
- Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 1992
- Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. Front Pharmacol 2025 (full text)
- Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab 2020
- Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes Care 2022
- Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S. Diabetes Obes Metab 2023
- Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes Obes Metab 2019
- ClinicalTrials.gov NCT03684642: Efpeglenatide versus dulaglutide in type 2 diabetes (AMPLITUDE-D)
- ClinicalTrials.gov NCT02075281: Effect of LAPS-Exendin on Body Weight in Obese Population (Hanmi)
- Dyson S et al. From Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists. Clin Dermatol 2026
- ClinicalTrials.gov NCT03496298: Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O)
- ClinicalTrials.gov NCT03713684: Efpeglenatide versus placebo added to basal insulin (AMPLITUDE-L)
- ClinicalTrials.gov NCT03770728: Efpeglenatide versus placebo added to metformin with or without sulfonylurea (AMPLITUDE-S)
- FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)
More in More GLP-1 drugs